Nocdurna (Desmopressin)

Desmopressin, the active ingredient in Nocdurna, is a vasopressin analog presented as a sublingual tablet for sublingual use. It is employed to manage central diabetes insipidus and nocturnal enuresis in patients who require reduced urine output and improved fluid balance.

GNH USA supplies Nocdurna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from consistent product availability, regulatory support, and comprehensive after‑sales service.

Desmopressin acts on the antidiuretic hormone pathway to reduce excessive urine production.

- Central diabetes insipidus: reduces polyuria, stabilizes fluid balance, and improves thirst control in affected individuals. - Nocturnal enuresis: decreases nighttime urine output, helping children and adults achieve better bladder control during sleep. - Mild hemophilia A: raises plasma factor VIII levels, providing temporary hemostatic support for minor surgical procedures or bleeding episodes.

Desmopressin may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dosing. - Nausea: transient feeling of stomach upset. - Nasal congestion: mild blockage or runny nose. - Hyponatremia (mild): low sodium levels without severe symptoms.

Serious or Rare Side Effects: - Severe hyponatremia: can lead to seizures, coma, or death. - Water intoxication: excessive water retention causing rapid weight gain and edema. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing desmopressin, clinicians should consider several safety precautions to minimize risk.

- Monitor serum sodium: check electrolytes regularly, especially in the first weeks of therapy. - Assess fluid intake: advise patients to limit excessive water consumption to prevent dilutional hyponatremia. - Review concomitant drugs: avoid or adjust dose when used with other antidiuretic agents or thiazide diuretics. - Caution in renal impairment: reduce dose or increase monitoring in patients with reduced kidney function. - Use in the elderly: start with the lowest effective dose and monitor closely for hyponatremia. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Desmopressin can interact with other medicines, altering its efficacy or increasing adverse effect risk.

Major Interactions (Avoid): - Concomitant use with other antidiuretic agents (e.g., chlorpropamide, carbamazepine): may cause severe hyponatremia. - Combination with thiazide diuretics: enhances water retention and electrolyte imbalance. - High‑dose NSAIDs: can potentiate antidiuretic effect, increasing hyponatremia risk.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor blood pressure and renal function. - CYP2C9 inhibitors (e.g., fluconazole): may increase desmopressin plasma levels. - Alcohol: can exacerbate side effects such as headache and nausea.